NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

CompletedN/A

Sponsor: LumiraDx UK Limited

Conditions: SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19

Interventions: LumiraDx SARS-CoV-2 & Flu A/B

Countries: United States

This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites. Subjects presenting with symptoms suggestive of coronavirus disease 2019 (COVID-19) and Influenza at the time of the study visit will be enrolled and asked to donate swab sample(s) for testing on the device under evaluation.

Eligibility overview

Sex: ALL

Age: 2 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Written informed consent obtained prior to study enrollment.
2. Male or female aged 2 years of age or older
3. Subject is currently exhibiting two or more symptoms associated with COVID-19 or influenza (such as, but not limited to, fever, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea) and must present within 6 days of symptom onset. Subject must still be exhibiting symptoms on the day of sample collection.

Exclusion Criteria:

1. Subject does not understand or is not able and willing to sign the study informed consent or be verbally assented.
2. Subject has had the seasonal influenza and/or the SARS-CoV-2 vaccine within the past 5 days.
3. Subject is not able to tolerate sample collection.
4. Subject is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®).
5. Subjects undergoing treatment currently and/or within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2.
6. Subjects who have taken Evusheld (tixagevimab/cilgavimab) within the last 90 days.
7. Subjects who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to study sample collection.
8. Subjects who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.

Locations (1)

Cullman, Alabama, United States